Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck

Annals of Oncology

Volumn 21, Issue 11, 2010, Pages 2284-2289

  Kuhnt, T ^a   Sandner, A ^b   Wendt, T ^c   Engenhart Cabillic, R ^d   Lammering, G ^e,f   Flentje, M ^g   Grabenbauer, G ^h   Schreiber, A ⁱ   Pirnasch, A ^a   Dunst, J ^j  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e MAASTRO CLINIC   (Netherlands)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g UNIVERSITY OF WÜRZBURG   (Germany)

^h KLINIKUM COBURG   (Germany)

ⁱ ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^j UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

more..

Author keywords

Cetuximab; Cisplatin; Hyperfractionated accelerated; Locally advanced SCCHN; Radiotherapy

Indexed keywords

CETUXIMAB; CISPLATIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DERMATITIS; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; FATIGUE; HEAD AND NECK CANCER; HUMAN; HYPERFRACTIONATED ACCELERATED RADIOTHERAPY; LEUKOCYTE COUNT; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; OUTCOME ASSESSMENT; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOTHERAPY; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK; STOMACH PERFORATION; STOMATITIS; THROMBOCYTE COUNT; VOMITING;

EID: 77958486627     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq216     Document Type: Article

References (20)

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Pivot X, Kataja VV, Jelic S. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol 2005; 16 (Suppl 1): 62-63.
3. Budach V, Stuschke M, Budach W et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 2005; 23: 1125-1135.
4. Denis F, Garaud P, Bardet E et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69-76.
5. Huguenin P, Beer KT, Allal A et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004; 22: 4665-4673.
6. Semrau R, Mueller RP, Stuetzer H et al. Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006; 64: 1308-1316.
7. Posner M. Evolving strategies for combined-modality therapy for locally advanced head and neck cancer. Oncologist 2007; 12: 967-974.
8. Pignon J-P, le Maître A, Maillard E, Bourhis J. on behalf of the MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
9. Budach W, Hehr T, Budach V et al. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006; 6: 28.
10. Bourhis J, Overgaard J, Audry H et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006; 368: 843-854.
11. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
12. Curran D, Giralt J, Harari PM et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007; 25: 2191-2197.
13. Caudell JJ, Sawrie SM, Spencer SA et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys 2008; 71: 676-681.
14. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
15. Pfister DG, Su YB, Kraus DH et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006; 24: 1072-1078.
16. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
17. Langer CJ, Lee JW, Patel UA et al. Preliminary analysis of ECOG 3303: concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). Oral presentation at the ASCO 2008 Annual Meeting, Chicago, IL. J Clin Oncol 2008; 26 (May 20 suppl): (Abstr 6006).
18. Medina JA, Rueda A, de Pasos AS et al. A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. Radiother Oncol 2006; 79: 34-38.
19. Ho KF, Swindell R, Brammer CV. Dose intensity comparison between weekly and 3-weekly cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: a retrospective comparison from New Cross Hospital, Wolverhampton, UK. Acta Oncol 2008; 47: 1-6.
20. Ang KK. Multidisciplinary management of locally advanced SCCHN: optimizing treatment outcomes. Oncologist 2008; 13: 889-910.